OM

Outset Medical, Inc. (OM) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

Outset Medical, Inc. is a medical technology company developing the Tablo® Hemodialysis System, a compact console designed to simplify dialysis delivery across hospital, clinic, and home settings. This report covers the quarterly period ended June 30, 2026, and the six-month period ended on the same date. The company operates as a single segment focused on the sale of consoles, consumables, and related services.

Key Financial Metrics

Note: Cash and cash equivalents were $35,005 and short-term investments were $112,189 as of June 30, 2026.

Material Changes vs. Prior Comparable Period

• Revenue: Total revenue increased slightly by 1% ($216k) for the three months ended June 30, 2026, compared to the prior year, driven by a 17% increase in service revenue. However, for the six-month period, total revenue decreased by 3% ($1.7M) due to a 9% decline in product revenue (specifically a $2.7M drop in consumables).
• Gross Margin: Gross margin improved significantly, rising 4.2 percentage points to 42.0% for the quarter and 5.2 percentage points to 42.7% for the six-month period, primarily due to higher margins on service revenue.
• Operating Expenses: Sales and marketing expenses decreased by 15% ($2.1M) for the quarter due to lower headcount and compensation costs. Conversely, General and Administrative (G&A) expenses increased by 24% ($2.2M) for the quarter, largely attributed to higher legal costs related to ongoing litigation.
• Net Loss: Net loss narrowed by 3% for the quarter and 17% for the six-month period compared to the prior year, aided by the absence of a $7.7M loss on extinguishment of a term loan recorded in the prior year's six-month period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: As of June 30, 2026, the company held approximately $151.0 million in cash, cash equivalents, restricted cash, and short-term investments. Management believes these resources are sufficient to meet needs for at least the next 12 months.
• Debt Covenants: The company is subject to the Perceptive Credit Agreement, which includes a $100 million term loan and an available $25 million delayed draw. Covenants require maintaining a minimum cash balance of $10.0 million and achieving specific trailing twelve-month net revenue targets. On August 5, 2026, the company amended this agreement to adjust revenue targets and reset the warrant exercise price to $4.838.
• Litigation: The company is involved in consolidated stockholder class action lawsuits alleging false statements regarding the Tablo system's marketing and FDA processes. A motion to dismiss is set for hearing in September 2026. The company cannot currently estimate potential losses.
• Regulatory Risks: In Q3 2026, the FDA issued a Form 483 following an inspection of the San Jose facility. The company intends to respond but notes there is no guarantee of a timely resolution without significant cost.
• Macroeconomic Factors: Rising interest rates and cautious capital spending by hospital customers have elongated sales cycles. Potential tariffs on imports from Mexico and China pose a risk to supply chain costs, though the company currently believes its products are exempt.

Key Facts for Investor Verification

• Verify the status of the FDA Form 483 issued in Q3 2026 and the company's response timeline.
• Monitor the progress of the consolidated securities litigation and the outcome of the motion to dismiss scheduled for September 2026.
• Confirm compliance with the amended revenue covenants under the Perceptive Credit Agreement to avoid an event of default.
• Assess the sustainability of the gross margin improvement given the decline in high-margin consumable revenue.
• Review the impact of macroeconomic conditions and potential tariff changes on the company's supply chain and customer capital spending.